Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control

Table 1

Clinical trial articles of MSCs in the treatment of liver cirrhosis in PubMed.

Types of liver cirrhosis	Resource of MSC	Dose and passage	Administration times and method	Effect	Country	Reference
HBV-related decompensated liver cirrhosis	UC	/kg body weight; The fourth passage	Intravenously three times at 4-week intervals	Well tolerated, significantly improves long-term survival rate, and the liver function	China	[111]
HBV-related decompensated liver cirrhosis	UC	/kg body weight; The fourth passage	Intravenously three times at 4-week intervals	Well tolerated, a significant reduction in the volume of ascites, and improves liver function	China	[112]
Liver cirrhosis caused by autoimmune diseases	UC, CB, BM	/kg body weight; The second and fifth passage	Peripheral vein one time	Well tolerated, alanine transaminase values decreased without statistical significance, total bilirubin decreased, serum albumin levels improved, a lowering of prothrombin time, and MELD score improved	China	[113]
Decompensated liver cirrhosis	BM	mean value; —	Peripheral vein once	Well tolerated, MELD score improved, the quality of life improved	Iran	[114]
Decompensated liver cirrhosis	BM	median value; Third or fourth passage	Cubital vein once	No beneficial effect	Iran	[115]
HBV, HCV, and alcohol-related liver cirrhosis or cryptogenic liver cirrhosis	BM		Portal vein/peripheral vein once	Well tolerated, improved liver function, decreased creatinine, increased serum albumin	Sweden	[116]
Liver cirrhosis	Adipose	—	Intrahepatic injection once	Well tolerated, improved liver function, increased METAVIR score, Child-Pugh score and MELD score, enhanced quality of life	China	[117]
Ursodeoxycholic acid- (UDCA-) resistant primary biliary cirrhosis	BM	/kg body weight; The third to fifth passage	Intravenously once	Well tolerated, the life quality and liver function improved, CD8+ T cells reduced, CD4+ CD25+ Foxp3+ T cells increased, serum IL-10 elevated	China	[57]
Alcoholic cirrhosis	BM	—	Femoral artery to hepatic artery one time or twice at 30-day intervals	Well tolerated, collagen reduced, Child-Pugh score improved	South Korea	[118]
Primary biliary cirrhosis with an incomplete response to UDCA	UC	/kg body weight; The fourth passage	Peripheral vein three times at 4-week intervals	Well tolerated, fatigue and pruritus obviously alleviated, liver function improved	China	[119]
HCV-related liver cirrhosis	BM	/kg body weight BM-derived undifferentiated and differentiated MSCs; —	Intravenously once	Liver function improved	Egypt	[120]
HBV-related liver cirrhosis	BM	—; —	Femoral artery to hepatic artery once	Liver function improved, Treg cells significantly increased, Th17 cells markedly decreased, mRNA levels of Treg-related transcription factor (Foxp3) and Th17-related transcription factor (RORγt) increased and decreased, serum TGF-β increased at early times of transplantation, serum IL-17, TNF-α, IL-6 reduced	China	[58]
HCV-related end-stage liver diseases	BM	^/kg body weight; —	Intravenously once	Liver function improved, collagen decreased without statistical significance	Egypt	[121]
Alcoholic liver cirrhosis	BM	—	Hepatic artery twice at 4-week intervals	Well tolerated, histological improvement, the Child-Pugh score improved, TGF-β1, type I collagen and α-SMA decreased	Korea	[122]
HBV-related decompensated liver cirrhosis	UC	The second passage	Intravenously at the third day and fourth day after conventional treatment	Well tolerated, IL-6, TNF-α, and TGF-β increased, IL-10 increased, CD4+ T cells and regulatory T cells elevated, CD8+ T cells and B cells reduced, liver function improved, MELD and Child-Pugh scores improved, mortality rate downregulated	China	[27]